COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,696 Articles (22,913 medRxiv, 8,783 bioRxiv)

Most recent first Previous |  Page 1237: Articles 12361-12370  | Next

2-Deoxy-D-Glucose as an Adjunct to Standard of Care in the Medical Management of COVID-19: A Proof-of-Concept & Dose-Ranging Randomised Clinical Trial
Bhatt, A. N., Shenoy, S., Munjal, S., Chinnadurai, V., Agarwal, A., Kumar, A. V., Shanavas, A., Kanvar, R., Chandna, S.
10.1101/2021.10.08.21258621 — Posted: 2021-10-10
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Dunkle, L. M., Kotloff, K. L., Gay, C. L., Anez, G., Adelglass, J. M., Barrat Hernandez, A. Q., Harper, W. L., Duncanson, D. M., McArthur, M. A., Florescu, D. F., McClelland, S., Garcia-Fragoso, V., Riesenberg, R. A., Musante, D. B., Fried, D. L., Safirstein, B. E., McKenzie, M., Jeanfreau, R. J., Kingsley, J. K., Henderson, J. A., Lane, D. C., Ruiz-Palacios, G. M., Corey, L., Neuzil, K. M., Coombs, R. W., Greninger, A. L., Hutter, J., Ake, J. A., Smith, K., Woo, W., Cho, I., Glenn, G. M., Dubovsky, F.
10.1101/2021.10.05.21264567 — Posted: 2021-10-10 Discussion: Onsite
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
Kraynyak, K. A., Blackwood, E., Agnes, J., Tebas, P., Giffear, M., Amante, D., Reuschel, E. L., Purwar, M., Christensen-Quick, A., Liu, N., Andrade, V., Diehl, M., Wani, S., Lupicka, M., Sylvester, A., Morrow, M. P., Pezzoli, P., McMullan, T., Kulkarni, A. J., Zaidi, F. I., Frase, D., Liaw, K., Smith, T. R. F., Ramos, S. J., Ervin, J., Adams, M., Lee, J., Dallas, M., Shah Brown, A., Shea, J. E., Kim, J. J., Weiner, D. B., Broderick, K. E., Humeau, L. M., Boyer, J. D., Mammen, M. P.
10.1101/2021.10.06.21264584 — Posted: 2021-10-10
Comparing lateral flow testing with a rapid RT-PCR method for SARS-CoV-2 detection in the UK
Taylor, A., Calvez, R. M., Atkins, M., Fink, C. G.
10.1101/2021.10.08.21264742 — Posted: 2021-10-10
Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study
Sridhar, S., Arnel, J., Bonaparte, M. I., Bueso, A., Chabanon, A.-L., Chen, A., Chicz, R. M., Diemert, D., Essink, B. J., Fu, B., Grunenberg, N. A., Janosczyk, H., Keefer, M. C., Rivera M, D. M., Meng, Y., Michael, N. L., Munsiff, S. S., Ogbuagu, O., Raabe, V. N., Severance, R., Rivas, E., Romanyak, N., Rouphael, N. G., Schuerman, L., Sher, L. D., Walsh, S. R., White, J., von Barbier, D., de Bruyn, G., Canter, R., Grillet, M.-H., Keshtkar-Jahromi, M., Koutsoukos, M., Lopez, D., Masotti, R., Mendoza, S., Moreau, C., Ceregido, M. A., Ramirez, S., Said, A., Tavares-Da-Silva, F., Shi, J., Tong, T., Treanor, J., Diazgranados, C. A., Savarino, S.
10.1101/2021.10.08.21264302 — Posted: 2021-10-10
Immunogenicity of the Ad26.CoV2.S vaccine in people living with HIV
Khan, K., Lustig, G., Bernstein, M., Archary, D., Cele, S., Karim, F., Smith, M., Ganga, Y., Jule, Z., Reedoy, K., Miya, Y., Mthabela, N., COMMIT-KZN Team, , Lessells, R., de Oliveira, T., Gosnell, B., Karim, S. A., Garrett, N., Hanekom, W., Gail Bekker, L., Gray, G., Blackburn, J. M., Moosa, M.-Y. S., Sigal, A.
10.1101/2021.10.08.21264519 — Posted: 2021-10-10
Taste loss as a distinct symptom of COVID-19: A systematic review and meta-analysis
Hannum, M. R., Koch, R., Ramirez, V., Marks, S., Toskala, A., Herriman, R., Lin, C., Joseph, P. V., Reed, D. R.
10.1101/2021.10.09.21264771 — Posted: 2021-10-09
COVID-19 Pandemic Impact on Sexually Transmitted Infection Testing in a College Setting
Marconi, A. M., Falk-Hanson, E. C., Crass, M. E., Campbell, P.
10.1101/2021.10.08.21264716 — Posted: 2021-10-09
COVID-19 Vaccine Effectiveness by Product and Timing in New York State
Rosenberg, E., Dorabwila, V., Easton, D., Bauer, U., Kumar, J., Hoen, R., Hoefer, D., Wu, M., Lutterloh, E., Conroy, M. B., Greene, D., Zucker, H. A.
10.1101/2021.10.08.21264595 — Posted: 2021-10-09 Discussion: Onsite
Plant Formulation ATRICOV 452 in Improving the Level of COVID-19 Specific Inflammatory Markers in Patients
Damle, L., Damle, H., BR, B.
10.1101/2021.10.07.21264491 — Posted: 2021-10-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).